EYEN
Price:
$0.0845
Market Cap:
$9.42M
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development progr...[Read more]
Industry
Biotechnology
IPO Date
2018-01-25
Stock Exchange
NASDAQ
Ticker
EYEN
According to Eyenovia, Inc.’s latest financial reports and current stock price. The company's current ROE is -1243.79%. This represents a change of 1.04% compared to the average of -108.76% of the last 4 quarters.
The mean historical ROE of Eyenovia, Inc. over the last ten years is -148.12%. The current -1243.79% ROE has changed 739.70% with respect to the historical average. Over the past ten years (40 quarters), EYEN's ROE was at its highest in in the June 2024 quarter at 466.42%. The ROE was at its lowest in in the March 2024 quarter at -600.85%.
Average
-148.12%
Median
-128.67%
Minimum
-302.93%
Maximum
-63.48%
Discovering the peaks and valleys of Eyenovia, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 153.48%
Maximum Annual ROE = -63.48%
Minimum Annual Increase = -50.67%
Minimum Annual ROE = -302.93%
Year | ROE | Change |
---|---|---|
2023 | -302.93% | 88.27% |
2022 | -160.90% | 153.48% |
2021 | -63.48% | -50.67% |
2020 | -128.67% | -28.03% |
2019 | -178.78% | 74.86% |
2018 | -102.24% | 1.46% |
2017 | -100.77% | -14.18% |
2016 | -117.43% | -34.00% |
The current ROE of Eyenovia, Inc. (EYEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-175.77%
5-year avg
-166.95%
10-year avg
-148.12%
Eyenovia, Inc.’s ROE is less than Reviva Pharmaceuticals Holdings, Inc. (1.15%), greater than Cidara Therapeutics, Inc. (-219.21%), greater than Fortress Biotech, Inc. (-240.30%), less than Selecta Biosciences, Inc. (19.45%), less than Reviva Pharmaceuticals Holdings, Inc. (1.15%), greater than Cognition Therapeutics, Inc. (-150.93%), greater than TransCode Therapeutics, Inc. (-649.01%), greater than Kodiak Sciences Inc. (-84.52%), greater than BioLineRx Ltd. (-163.37%), greater than Ardelyx, Inc. (-46.60%), greater than Lexicon Pharmaceuticals, Inc. (-107.38%), less than Seres Therapeutics, Inc. (60.75%), less than ImmunityBio, Inc. (86.39%), greater than Alpha Tau Medical Ltd. (-38.62%), greater than Ocular Therapeutix, Inc. (-56.75%), greater than Tenaya Therapeutics, Inc. (-86.16%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Greenwich LifeSciences, Inc. (-185.11%), greater than Immutep Limited (-14.12%), greater than Anavex Life Sciences Corp. (-30.63%),
Company | ROE | Market cap |
---|---|---|
1.15% | $76.39M | |
-219.21% | $164.89M | |
-240.30% | $48.03M | |
19.45% | $135.20M | |
1.15% | $63.10M | |
-150.93% | $25.51M | |
-649.01% | $2.49M | |
-84.52% | $486.77M | |
-163.37% | $19.41M | |
-46.60% | $1.08B | |
-107.38% | $298.95M | |
60.75% | $164.78M | |
86.39% | $1.95B | |
-38.62% | $215.37M | |
-56.75% | $1.35B | |
-86.16% | $125.96M | |
-88.42% | $193.36M | |
-185.11% | $159.84M | |
-14.12% | $288.21M | |
-30.63% | $948.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eyenovia, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eyenovia, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Eyenovia, Inc.'s ROE?
How is the ROE calculated for Eyenovia, Inc. (EYEN)?
What is the highest ROE for Eyenovia, Inc. (EYEN)?
What is the 3-year average ROE for Eyenovia, Inc. (EYEN)?
What is the 5-year average ROE for Eyenovia, Inc. (EYEN)?
How does the current ROE for Eyenovia, Inc. (EYEN) compare to its historical average?